The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis.

[1]  M. Suarez‐Almazor,et al.  Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. , 1998, The Journal of rheumatology.

[2]  C. Wallace,et al.  The use of methotrexate in childhood rheumatic diseases. , 1998, Arthritis and rheumatism.

[3]  A. Martini,et al.  Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. , 1998, Clinical and experimental rheumatology.

[4]  G. Keenan,et al.  Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. , 1997, Pediatrics.

[5]  K. Bove,et al.  The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. , 1997, Arthritis and rheumatism.

[6]  R. Goldbach-Mansky,et al.  Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. , 1997, Rheumatic diseases clinics of North America.

[7]  D. Lovell.  Ten years of experience with methotrexate. Past, present and future. , 1997, Revue du rhumatisme.

[8]  D. Felson,et al.  Preliminary definition of improvement in juvenile arthritis. , 1997, Arthritis and rheumatism.

[9]  A. Martini,et al.  Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. , 1997, The Journal of rheumatology.

[10]  D. Glass,et al.  Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome. , 1997, The Journal of rheumatology.

[11]  A. Martini,et al.  Correlation between conventional disease activity measures in juvenile chronic arthritis , 1997, Annals of the rheumatic diseases.

[12]  A. Martini,et al.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. , 1996, The Journal of pediatrics.

[13]  M. Gattinara,et al.  Validation of the Italian version of the Stanford Childhood Health Assessment Questionnaire for measuring functional status in children with chronic arthritis. , 1995, Clinical and experimental rheumatology.

[14]  A. Martini,et al.  Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. , 1995, The Journal of rheumatology.

[15]  Hardin Jg,et al.  Underrecognized postdosing reactions to methotrexate in patients with rheumatoid arthritis. , 1994 .

[16]  J. Cassidy,et al.  Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. , 1992, The New England journal of medicine.

[17]  B. Myones,et al.  Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. , 1992, The Journal of pediatrics.

[18]  A. Martini,et al.  Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[19]  A. Prieur,et al.  Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. , 1991, Clinical and experimental rheumatology.

[20]  K. Bove,et al.  The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. , 1999, The Journal of pediatrics.

[21]  M. Nordin,et al.  Early predictors of outcome. , 1996, Bulletin (Hospital for Joint Diseases (New York, N.Y.)).

[22]  A. Reiff,et al.  High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. , 1995, Clinical and experimental rheumatology.